Resource for Clinical Studies of AKI (Clinical Research/Genomics/Biorepository)

AKI 临床研究资源（临床研究/基因组学/生物样本库）

• 批准号: 8625439
• 负责人: Ravindra L. Mehta
• 金额: $ 29.94万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8625439
• 关键词: Acute Renal Failure with Renal Papillary Necrosis; Adult; Basic Science; Biological; Biological Assay; Biological Markers; Cessation of life; Childhood; Chronic Kidney Failure; Clinical; Clinical Data; Clinical Research; Clinical Trials; Coupled; DNA; Databases; Diagnosis; Disease; Functional disorder; Genetic Determinism; Genomics; Goals; Hospitalization; Human; Human Resources; Individual; Injury; Instruction; International; Investigation; Kidney; Knowledge; Lead; Link; Natural History; Online Systems; Outcome; Pathway interactions; Patients; Pharmaceutical Preparations; Phenotype; Prospective Studies; Protocols documentation; Publications; Registries; Renal function; Research; Research Personnel; Resources; Risk; Sampling; System; Translational Research; Translations; base; biobank; data acquisition; data management; design; flexibility; follow-up; improved; insight; international center; longitudinal course; novel; repository; research study; tool

PROJECT SUMMARY (See instructions): Clinical and translational research in acute kidney injury (AKI) requires well designed prospective studies as well as access to well characterized patients with longitudinal follow up coupled with biological samples enabling investigators to probe the underlying mechanisms and pathways contributing to outcomes. The specific aims of the Resource for Clinical Studies of AKI (Core A) are to 1) provide core resources to support the design and conduct of clinical research In AKI, 2) provide a genomics resource to perform systematic genomic analyses and allow correlation with clinical phenotypic information, and 3) provide a biological sample repository linked to the clinical and genomics database for the characterization of patients for our investigator base. This core will specifically provide investigators access to patients with AKI through an established international network of collaborating investigators who are contributing to an ongoing registry of AKI in the ICU setting currently with over 1000 patients, access to biological samples including DNA from patients and healthy controls and protocols and tools for quantitative assessment of changes in kidney function. Since its inception the Core has been successful in supporting investigators for clinical and translational research. The Core has established a robust data management system and database of patients with AKI that Is flexible In accommodating the research objectives of individual investigators and collaborating centers; currently supporting 5 large multicenter projects including the AKI registry and an international prospective study for the genomics of drug-induced kidney injury. The genomics resource has facilitated the investigation of genetic determinants (both risk and outcome) of AKI, and identified novel genomic predictors of the longitudinal course in AKI. Over 14,000 biomarker assays incorporating more than 20 analytes have been performed to support both pediatric and adult AKI research. A biological sample repository has been established and has >2000 sequential samples from well-characterized patients with and without AKI. The Core has supported 143 projects for 52 investigators (including 4 pilot recipients and 45 non-core personnel), resulting in 57 publications. These rich resources will continue to enable interdisciplinary clinical investigation in AKI to advance our understanding of the natural history, pathophysiology and treatment of human AKI. Core A in conjunction with existing resources at UAB and UCSD and other cores within the O'Brien center will accelerate the translation of new investigative insights towards improving outcomes for patients with AKI

项目概述（见说明）：急性肾损伤（AKI）的临床和转化研究需要精心设计的前瞻性研究，以及对具有良好特征的患者进行纵向随访，并结合生物样本，使研究人员能够探索促成结果的潜在机制和途径。AKI临床研究资源（Core A）的具体目标是：1)提供核心资源，以支持AKI临床研究的设计和实施；2)提供基因组学资源，以进行系统的基因组分析，并允许与临床表型信息相关联；3)为我们的研究者基础提供与临床和基因组学数据库相关联的生物样本库，以表征患者。该核心将通过一个已建立的国际合作研究网络，专门为研究人员提供AKI患者的访问权限，这些研究人员正在为ICU环境中超过1000名患者的AKI注册做出贡献，获得生物样本，包括来自患者和健康对照的DNA，以及用于定量评估肾功能变化的协议和工具。自成立以来，该中心已成功地支持研究人员进行临床和转化研究。核心已经建立了一个强大的数据管理系统和AKI患者数据库，可以灵活地适应个体研究者和合作中心的研究目标；目前支持5个大型多中心项目，包括AKI注册和药物性肾损伤基因组学的国际前瞻性研究。基因组学资源促进了AKI遗传决定因素（包括风险和结果）的研究，并确定了AKI纵向病程的新的基因组预测因子。为了支持儿科和成人AKI的研究，已经进行了超过14,000项生物标志物分析，其中包括20多种分析物。已经建立了一个生物样本库，并从具有良好特征的AKI患者和非AKI患者中收集了2000个顺序样本。核心资助了52名研究人员（包括4名试点受助人和45名非核心人员）的143个项目，发表了57份出版物。这些丰富的资源将继续促进AKI的跨学科临床研究，以促进我们对人类AKI的自然历史、病理生理和治疗的理解。Core A与UAB和UCSD的现有资源以及O'Brien中心的其他核心相结合，将加速新的研究见解的转化，以改善AKI患者的预后